Naim Alkhouri joins Louise Campbell and Roger Green to discuss some of his recent investigator-initiated research projects that focus on future NASH therapies. These include a project evaluating the impact of the behavioral diet app Noom on liver health and a series of others evaluating digital therapeutics and their ability to improve patients’ liver health.
Louise Campbell and Roger Green interview Arizona Liver Health Institute V.P. of Academic Affairs and Fatty Liver Program Director Naim Alkhouri and Global Liver Institute Founder and CEO Donna Cryer about their recent projects and accomplishments.
Learn about the amazingly diverse and exciting program for Day Two of the inaugural Innovations in NAFLD Care 2022 Workshop, with sessions on Comprehensive Care pathways, current and future pharmacotherapies, and what a future integrated treatment roadmap might look like.
Did you ever wonder why leaders believe the care continuum necessary to bring the NASH pandemic under control will require so many types of healthcare providers and such a broad effort?
Learn about the history and interests that led Professors Jeff Lazarus and Jörn Schattenberg to launch the Innovations in NAFLD Care 2022 Workshop
This episode focuses on the history of single-cell genomics up through spatial transcriptomics and beyond and raises questions about the new things we can learn and the demand these improved techniques place on other elements in the research process.
What are the implications of the targeted NASH therapies of the future on NASH drug development today?
Scott Friedman discusses that background for the potential breakthrough work from Jon Epstein at the University of Pennsylvania on how combined mRNA/CAR-T therapy can regress fibrosis in mouse CVD models.
What do recent findings in mRNA/CAR-T anti-fibrotic therapies and advanced NASH omics promise for the future of treating NAFLD and NASH?
This Episode is Sponsored by Madrigal Pharmaceuticals: CLDF opted for a Liver Connect program that featured conversations between sizable groups of experts instead of lengthy scientific presentations. How well did it work for panelists?
